Cancer Treatment Drug

The international blockade of Gaza and the continued illegal collective punishment of its residents by Israel has resulted in soaring food prices (eg. a bag of flour has risen from 80 shekels to over 200 shekels ie. A $23 to A $57). In addition, many foodstuffs, medicines and other goods, such as building material are no longer available. According to the United Nations Office for Coordination for Humanitarian Affairs in the Occupied Palestinian Territories there are zero stocks available for 91 drugs. Hospitals are reporting zero stock availability of pediatric drugs and anti-biotics, as well as a shortage in chronic disease drugs, cancer treatment drugs, a range of kidney dialysis drugs and IV glucose solution. In addition, there are also shortages of kidney dialysis machine equipment.

Fuel which is needed for just about everything, including cooking, running hospitals, schools, purifying, sterilising and pumping water, running garbage collection trucks, ambulances and much more is increasing scarce and expensive.

Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT ...

SEATTLE, Oct. 23 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the Company has completed enrollment of over 500 patients in the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The IMPACT study is a double-blind, randomized, placebo-controlled Phase 3 trial designed to measure overall survival in men with metastatic hormone-refractory prostate cancer receiving PROVENGE versus placebo.

Earlier this year, following a positive recommendation from an outside panel of experts, Dendreon received a complete response letter from the U.S. Food and Drug Administration (FDA) that asked for additional evidence that would support the efficacy of PROVENGE.

Scientists Develop New Drug To Outflank Cancer Resistance, UK

A new drug has shown promising results against breast and prostate cancer cells and tumours that are resistant to conventional hormone-based treatments, according to research published in the British Journal of Cancer.

Cancers such as breast and prostate cancer are often fuelled by sex hormones, such as oestrogen or testosterone. Hormone therapy for breast or prostate cancer aims to reduce the levels of these hormones in the body, "starving" the cancer of these signals and halting tumour growth. Some cancers are resistant to this treatment from the outset while many build up a resistance to these drugs over time, their growth becoming hormone-independent - such cancers are a major challenge to treat.

Now, researchers have shown that a new drug - STX140 - directly targets hormone-independent cancer cells by initiating a natural suicide process within them.